Cullinan Therapeutics Inc
CGEM
Company Profile
Business description
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
Contact
One Main Street
Suite 1350
CambridgeMA02142
USAT: +1 617 410-4650
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
111
Stocks News & Analysis
stocks
After earnings, is Uber stock a buy, a sell, or fairly valued?
With results exceeding management’s forecast for Q3, here’s what we think of Uber stock.
stocks
The largest share trading on the ASX remains materially overvalued
Profit barely budges on the most expensive bank in the world.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,110.80 | 6.60 | -0.07% |
| CAC 40 | 8,156.23 | 0.00 | 0.00% |
| DAX 40 | 24,088.06 | 128.07 | 0.53% |
| Dow JONES (US) | 47,927.96 | 559.33 | 1.18% |
| FTSE 100 | 9,899.60 | 112.45 | 1.15% |
| HKSE | 26,696.41 | 47.35 | 0.18% |
| NASDAQ | 23,468.30 | 58.87 | -0.25% |
| Nikkei 225 | 50,887.76 | 44.83 | 0.09% |
| NZX 50 Index | 13,655.62 | 51.07 | 0.38% |
| S&P 500 | 6,846.61 | 14.18 | 0.21% |
| S&P/ASX 200 | 8,830.30 | 5.70 | -0.06% |
| SSE Composite Index | 4,002.76 | 15.84 | -0.39% |